CI
CIPLA
CIPLA Cipla Q1 FY26 results (Apr–Jun 2025) and concall
As Cipla celebrated its 90th anniversary, the company delivered steady Q1 FY26 performance despite seasonal headwinds in respiratory and anti-infective segments. Strong execution across geographies and successful new product launches positioned the company for sustained growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 4,971 | 4,798 | 5,046 |
| EBITDA | 1,662 | 1,319 | 1,624 |
| Net profit | 1,438 | 1,485 | 1,303 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
